vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Spok Holdings, Inc (SPOK). Click either name above to swap in a different company.
Spok Holdings, Inc is the larger business by last-quarter revenue ($33.9M vs $18.6M, roughly 1.8× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 8.7%, a 57.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -0.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -1.5%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Spok Holdings, Inc. is a global provider of critical communication solutions primarily serving the healthcare industry. It offers unified clinical communication platforms, secure messaging tools, alerting systems, and on-call scheduling software that help care teams coordinate efficiently, cut response times, and boost patient safety across medical facilities.
SCYX vs SPOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $33.9M |
| Net Profit | $12.3M | $2.9M |
| Gross Margin | — | 76.7% |
| Operating Margin | 56.3% | 11.6% |
| Net Margin | 65.7% | 8.7% |
| Revenue YoY | 1808.5% | -0.1% |
| Net Profit YoY | 376.5% | -19.6% |
| EPS (diluted) | $0.25 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $33.9M | ||
| Q3 25 | $334.0K | $33.9M | ||
| Q2 25 | $1.4M | $35.7M | ||
| Q1 25 | $257.0K | $36.3M | ||
| Q4 24 | $977.0K | $33.9M | ||
| Q3 24 | $660.0K | $34.9M | ||
| Q2 24 | $736.0K | $34.0M | ||
| Q1 24 | $1.4M | $34.9M |
| Q4 25 | $12.3M | $2.9M | ||
| Q3 25 | $-8.6M | $3.2M | ||
| Q2 25 | $-6.9M | $4.6M | ||
| Q1 25 | $-5.4M | $5.2M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $-2.8M | $3.7M | ||
| Q2 24 | $-14.5M | $3.4M | ||
| Q1 24 | $411.0K | $4.2M |
| Q4 25 | — | 76.7% | ||
| Q3 25 | — | 78.3% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 80.1% | ||
| Q4 24 | — | 78.5% | ||
| Q3 24 | — | 79.5% | ||
| Q2 24 | — | 78.9% | ||
| Q1 24 | — | 79.5% |
| Q4 25 | 56.3% | 11.6% | ||
| Q3 25 | -2516.5% | 12.9% | ||
| Q2 25 | -701.0% | 15.1% | ||
| Q1 25 | -3350.2% | 16.6% | ||
| Q4 24 | — | 13.7% | ||
| Q3 24 | -1563.6% | 14.2% | ||
| Q2 24 | -1255.0% | 13.2% | ||
| Q1 24 | -692.5% | 14.0% |
| Q4 25 | 65.7% | 8.7% | ||
| Q3 25 | -2572.2% | 9.5% | ||
| Q2 25 | -504.8% | 12.8% | ||
| Q1 25 | -2097.7% | 14.3% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | -425.5% | 10.5% | ||
| Q2 24 | -1964.4% | 10.1% | ||
| Q1 24 | 29.9% | 12.1% |
| Q4 25 | $0.25 | $0.13 | ||
| Q3 25 | $-0.17 | $0.15 | ||
| Q2 25 | $-0.14 | $0.22 | ||
| Q1 25 | $-0.11 | $0.25 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | $-0.06 | $0.18 | ||
| Q2 24 | $-0.30 | $0.17 | ||
| Q1 24 | $0.01 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $25.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $146.4M |
| Total Assets | $59.0M | $206.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $25.3M | ||
| Q3 25 | $37.9M | $21.4M | ||
| Q2 25 | $44.8M | $20.2M | ||
| Q1 25 | $40.6M | $19.9M | ||
| Q4 24 | $59.3M | $29.1M | ||
| Q3 24 | $68.8M | $27.8M | ||
| Q2 24 | $73.0M | $23.9M | ||
| Q1 24 | $80.2M | $23.3M |
| Q4 25 | $49.4M | $146.4M | ||
| Q3 25 | $36.4M | $148.7M | ||
| Q2 25 | $44.5M | $150.9M | ||
| Q1 25 | $50.5M | $151.7M | ||
| Q4 24 | $55.1M | $154.7M | ||
| Q3 24 | $58.5M | $156.3M | ||
| Q2 24 | $60.4M | $158.2M | ||
| Q1 24 | $74.1M | $160.2M |
| Q4 25 | $59.0M | $206.1M | ||
| Q3 25 | $51.1M | $209.7M | ||
| Q2 25 | $60.7M | $208.7M | ||
| Q1 25 | $67.9M | $204.5M | ||
| Q4 24 | $90.6M | $217.1M | ||
| Q3 24 | $99.0M | $216.8M | ||
| Q2 24 | $107.8M | $216.4M | ||
| Q1 24 | $118.3M | $215.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $11.5M |
| Free Cash FlowOCF − Capex | — | $10.1M |
| FCF MarginFCF / Revenue | — | 29.9% |
| Capex IntensityCapex / Revenue | — | 4.1% |
| Cash ConversionOCF / Net Profit | 1.50× | 3.93× |
| TTM Free Cash FlowTrailing 4 quarters | — | $25.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $11.5M | ||
| Q3 25 | $-8.7M | $8.1M | ||
| Q2 25 | $-7.5M | $7.0M | ||
| Q1 25 | $-7.5M | $2.3M | ||
| Q4 24 | $-24.0M | $8.4M | ||
| Q3 24 | $765.0K | $11.1M | ||
| Q2 24 | $-10.9M | $7.4M | ||
| Q1 24 | $-4.0M | $2.0M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | — | $10.3M | ||
| Q2 24 | — | $6.8M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | 29.9% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 22.3% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | — | 20.0% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.5% |
| Q4 25 | 1.50× | 3.93× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 1.55× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 3.03× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | -9.75× | 0.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
SPOK
| Paging | $16.8M | 50% |
| Software Operations | $16.0M | 47% |
| License | $1.2M | 4% |
